Abramovits W et al. Pralatrexate (Folotyn). Skinmed 2012;10(4):244-6. Abstract

Bolden JE at al. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84. Abstract

Cang S et al. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012;5:64. Abstract

Coiffier B et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6. Abstract

Coiffier B et al. Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update. Proc ASH 2012;Abstract 3641.

Coutre SE et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a Phase I study. Proc ASH 2012;Abstract 191.

Flinn IW et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study. Proc ASH 2012;Abstract 902.

Fowler NH et al. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a Phase II study. Proc ASH 2012;Abstract 901.

Kahl BS et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Proc ASH 2011;Abstract LBA-6.

Kluin-Nelemans HC et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31. Abstract

Kwon HJ et al. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97(3):290-6. Abstract

Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366(21):2008-16. Abstract

O’Connor OA et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9. Abstract

Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov 2003;2(8):611-2. Abstract

Peart MJ et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Nat Acad Sci 2005;102(10):3697-702. Abstract

Press OW, Palanca-Wessels MC. Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 2013;31(12):1496-8. Abstract

Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873);1203-10. Abstract

Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2010;377(9759):42-51. Abstract

Swerdlow SH et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.

Wang Y et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 2007;356(4):998-1003. Abstract

Wierda WG. Making advances in first-line chronic lymphocytic leukemia treatment. J Clin Oncol 2012;30(26);3162-4. Abstract

Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: The Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31(1):128-30. Abstract